AML1-ETO targets a distal NAT10 enhancer to alter glutathione metabolism in t(8;21) AML

Background and rationale

Chromosomal translocations in hematologic malignancies generate oncogenic fusion transcription factors that reprogram gene expression networks. One such fusion, AML1-ETO, is associated with t(8;21) acute myeloid leukemia (AML). Prior studies have shown AML1-ETO predominantly occupies gene promoters to alter transcription in leukemia stem cells (LSCs), contributing to leukemogenesis. The question addressed by the study was whether AML1-ETO is also recruited to distal regulatory DNA elements, such as enhancers, and whether such recruitment can drive oncogenic programs relevant to LSC maintenance.

Experimental approach and datasets

To map AML1-ETO genomic occupancy and active enhancer marks, the authors performed CUT&Tag profiling for AML1-ETO and H3K27ac. The profiling was applied to primary t(8;21) AML CD34+ cells and to established t(8;21) AML cell lines. These datasets were used to define landscapes of the fusion protein and active enhancers in the cellular contexts most relevant to t(8;21) disease biology.

AML1-ETO binding at a distal NAT10 enhancer

CUT&Tag analysis revealed AML1-ETO binding at a distal enhancer associated with the RNA N4-acetyltransferase gene NAT10 (the abstract truncates the gene descriptor as “RNA N4-acetylc…”). This observation indicates that AML1-ETO engagement is not limited to promoters but extends to at least one distal regulatory element that may control NAT10 expression.

The identification of AML1-ETO occupancy at a distal NAT10 enhancer supports a model in which fusion oncoproteins can hijack enhancers to reprogram transcriptional programs beyond proximal promoter regulation. The presence of H3K27ac at these loci, as profiled, is consistent with active enhancer status in the analyzed t(8;21) AML cells.

Link between NAT10, glutathione metabolism, and LSC stemness

The article title and the available abstract text state that AML1-ETO hijacking of the distal NAT10 enhancer results in reprogramming of glutathione metabolism and sustains leukemia stem cell stemness. This implies a mechanistic axis in which altered regulation of NAT10, driven by fusion protein binding at a distal enhancer, influences metabolic pathways (specifically glutathione-related redox metabolism) that are important for LSC maintenance.

However, the source excerpt is truncated and does not include experimental details, such as how NAT10 expression was measured, what specific changes in glutathione metabolism were observed, which assays were used to assess LSC stemness (for example, colony formation, serial transplantation, or flow cytometry markers), nor any molecular intermediates linking NAT10 activity to glutathione pathway modulation. These experimental particulars and quantitative results are not reported in the provided text and therefore cannot be restated here.

Limitations and missing reported details

The provided PubMed source text is incomplete. Missing items that were not reported in the excerpt include, but are not limited to:

• Specific genomic coordinates or sequences of the identified distal NAT10 enhancer.
• Quantitative changes in NAT10 mRNA or protein following AML1-ETO binding.
• Direct mechanistic evidence linking NAT10 activity to alterations in glutathione synthesis, recycling, or redox balance.
• Functional experiments demonstrating causality between enhancer hijacking, NAT10 modulation, metabolic changes, and maintenance of LSC properties.
• Any in vivo validation (mouse models, xenografts) or clinical correlations using patient outcome data.
• Details on sample sizes, statistical analyses, and effect sizes.

Because these elements are absent from the supplied abstract fragment, they are not asserted here.

Potential clinical implications and next steps

Based on the study framing, the recruitment of AML1-ETO to a distal enhancer of NAT10 and the reported connection to glutathione metabolism suggest possible translational avenues: targeting the fusion-driven enhancer interaction, NAT10 enzymatic activity, or glutathione/redox homeostasis might influence LSC survival in t(8;21) AML. However, specific therapeutic strategies, preclinical evaluation, or safety data are not described in the provided content and cannot be inferred.

Future work (not detailed in the source excerpt) that would be necessary to establish clinical relevance includes:

• Validated mechanistic experiments showing that disrupting AML1-ETO binding to the enhancer or inhibiting NAT10 reverses metabolic reprogramming and impairs LSC function.
• In vivo efficacy studies and toxicity assessment of candidate interventions.
• Correlative analyses in patient cohorts linking NAT10 enhancer status or NAT10 expression to clinical outcomes.

Conclusions

The available PubMed abstract indicates that AML1-ETO occupies a distal enhancer of NAT10 in t(8;21) AML and that this interaction is associated with reprogramming of glutathione metabolism and support of leukemia stem cell stemness. The study applied CUT&Tag to define AML1-ETO and H3K27ac landscapes in primary CD34+ t(8;21) AML cells and t(8;21) AML cell lines, and it reports enhancer engagement by the fusion protein.

The source excerpt is truncated and omits experimental details, quantitative findings, and validation data; those items are not reported here. For comprehensive evaluation of methods, results, and therapeutic implications, consult the full published article (Proc Natl Acad Sci U S A; DOI 10.1073/pnas.2608310123; PMID 42679037).